

1 Treatment interventions and assessment of fear-avoidance  
2 for chronic musculoskeletal pain: a systematic review  
3 protocol  
4

5 Authors: Tan, S.<sup>1¶</sup>, Jaggi, A.<sup>2&</sup>, Tasker, A.<sup>3&</sup>, Borra, C.<sup>4&</sup>, & Watson, F.<sup>5\*¶</sup>

6 <sup>1</sup>University College London, London, United Kingdom  
7

8 <sup>2</sup>Royal National Orthopaedic Hospital, London, United Kingdom  
9

10 <sup>3</sup>Bristol Veterinary School, University of Bristol, Bristol, United Kingdom  
11

12 <sup>4</sup>Institute of Education, University College London, London, United Kingdom; Trauma and  
13 Orthopaedics, Barts Health NHS Trust, London, United Kingdom; Bone & Joint Health, Queen Mary  
14 University of London, London, United Kingdom  
15

16 <sup>5</sup>Bioengineering, Imperial College London, London, United Kingdom  
17

18 \*Corresponding author

19 Email: [sam.tan.20@ucl.ac.uk](mailto:sam.tan.20@ucl.ac.uk)

20 <sup>¶</sup>These authors contributed equally to this work. FW is the guarantor. ST and FW drafted the  
21 manuscript. AJ and FW conducted the initial Patient and Public Involvement activity which informed  
22 the current search strategy design.

23 <sup>&</sup>These authors also contributed equally to this work. AT provided expertise in the data synthesis  
24 section. All authors read, provided feedback and approved the final manuscript.

25

26 Registration: To be completed following peer review.

## 27 **Abstract**

28 **Introduction:** The Fear-Avoidance (FA) model aims to explain how an acute pain experience can  
29 develop into a persistent state. The FA model considers five core components: kinesiophobia, pain-  
30 related fear, catastrophisation, victimisation, and interpersonal social environment. Amongst these,  
31 kinesiophobia, tends to dominate the literature on chronic musculoskeletal pain. As a result, current  
32 reviews have not considered the other core components of the FA model when exploring its  
33 interventions. Moreover, several synonyms of the term kinesiophobia is not reflected in their search  
34 strategies. Coupled with the preference of particular study designs and outcome measures, this  
35 systematic review aims to provide and characterise an overview of treatment interventions that  
36 consider all study designs, relevant outcome measures, FA components, and FA component  
37 synonyms.

38 **Methods and analysis:** Eligible studies will be in English or with an available English translation from  
39 1970 onwards. Databases to be searched include Cochrane Central Register of Controlled Trials  
40 (CENTRAL), MEDLINE, Embase, The Allied and Complementary Database (AMED), PEDro, Web of  
41 Science, and grey literature. We will include studies involving participants  $\geq 18$  years old with chronic  
42 musculoskeletal pain, and interventions targeting FA and/or its components. Three review authors  
43 will independently screen papers using preestablished eligibility criteria and conduct assessments of  
44 risk of bias, with a fourth independent researcher employed to resolve disagreements where found.  
45 Qualitative synthesis techniques will be used to characterise the interventions. Patient and Public  
46 Involvement (PPI) has been utilised to develop this protocol and will be conducted following  
47 completion of the systematic review to discuss and reflect on the findings.

48 **Ethics and dissemination:** This systematic review does not require ethical approval as existing data  
49 will be used and the PPI to be conducted is an involvement activity rather than study data. The  
50 results will be disseminated through a peer-reviewed journal and via national and international  
51 conferences.

52 **Prospero registration number:** [this protocol will be registered following peer review].

53 **Keywords:** kinesiophobia, chronic pain, musculoskeletal pain, fear, social environment, pain, fear-  
54 avoidance model

## 55 **Strengths and limitations of this study**

- 56 • This systematic review provides a meaningful and patient-centred search in the context of  
57 fear-avoidance (FA), as the search strategy purposively includes additional components of FA  
58 and its synonyms.
- 59 • The search strategy will include eight relevant measures and all study designs to provide a  
60 diverse overview of the current interventions for FA in chronic musculoskeletal conditions.
- 61 • Utilising a combination of established qualitative methods to identify and characterise  
62 interventions for fear avoidance and integrating them with the opinions of the PPI  
63 community collaborators to better appreciate multiple perspectives and inform further  
64 research.
- 65 • A meta-analysis is not considered due to the methodological heterogeneity of including all  
66 study designs, however it is not entirely applicable to the scoping objective of this systematic  
67 review.
- 68 • The inclusion of participants with comorbidities increases generalisability of results at the  
69 risk of introducing additional biases and confounders.


## 70 **Introduction**

### 71 **Rationale**

72 The Fear-Avoidance (FA) model was developed by Lethem et al in 1983 (26) to explain the pathways  
73 by which acute pain transitions to chronic using a biopsychosocial perspective (1, 2). According to  
74 the FA model, a self-reinforcing cycle of catastrophising, fear, hypervigilance, and further avoidance  
75 of movement can lead towards dysfunction, deconditioning, depression, and increased pain (3). The

76 FA model is made up of four main components: kinesiophobia, catastrophising, pain-related fear,  
 77 and FA beliefs (4, 5). Some researchers have suggested adding victimisation, disability, self-efficacy,  
 78 and input from the interpersonal social environment, suggesting that the model should extend  
 79 beyond pain-related fear and highlights the significance of concurrent, and often competing, goals  
 80 (2, 6-8) (Fig 1).

81 **Fig 1: The components of the Fear Avoidance model and potential implications.**



82  
 83 In the assessment and treatment of chronic musculoskeletal pain, kinesiophobia may be described  
 84 and understood by a range of synonyms (e.g., "fear of movement", "fear of (re)injury", "avoidance  
 85 behaviour", "avoidance hypervigilance", "behavioural performance", "pain-related fear with  
 86 impaired physical performance", and "avoidance of activity") which tend to dominate the research  
 87 landscape (9-11). Kinesiophobia is an important mediator of new and prolonged chronic pain and  
 88 disability, and as such is an important element of the FA paradigm; rates are estimated at 51-72% of  
 89 people with chronic pain (9, 12). Kinesiophobia presents a major challenge to successful physical  
 90 rehabilitation; unchecked, it may contribute to the development of disuse syndrome, which is  
 91 associated with additional physical and psychosocial impacts such as depression, muscle atrophy,

92 and medication misuse (13). These fundamental effects risk drawing practitioners focus away from  
93 less-reported aspects of the FA model.

94 Several systematic reviews have focused on the results of interventions to treat kinesiophobia (14-  
95 17); a focus which risks overlooking the multifactorial origins and drivers of chronic musculoskeletal  
96 pain. Bordeleau et al (9) recommends further research into the multi-faceted nature of  
97 kinesiophobia, encompassing physical, psychological, and social interventions. These concerns are  
98 further compounded by the nature and use of tools available to measure kinesiophobia; methods  
99 such as the Tampa Scale of Kinesiophobia (TSK) that is widespread and accessible (18). Liu et al  
100 conducted a review of related measures and found that The Fear-Avoidance Beliefs Questionnaire  
101 (FABQ) and TSK were the most often used questionnaires (19,20). Indeed, many systematic reviews  
102 have specified use of the TSK as part of their study inclusion criteria (9, 15). This further exacerbates  
103 the focus on kinesiophobia, and simultaneously dampens potential for assessment of the full FA  
104 model on chronic musculoskeletal pain. Moreover, current reviews have primarily included  
105 randomised controlled trials (RCT) in their search strategy, which restricts the diversity of  
106 interventions explored.

107 In addition to the TSK and FABQ, there are other FA model-adjacent measures including the  
108 Kinesiophobia Causes Scale (KCS) (21), Athlete Fear-avoidance Questionnaire (AFAQ) (5), and the  
109 Fear-Avoidance Components Scale (FACS) (7). Some researchers have started to use a combination  
110 of the aforementioned measures, but it is unknown whether this is appropriate given the potential  
111 for discordance between each measure and the FA model construct (9, 22-24).

112 The current literature on assessing FA and its components, beyond just kinesiophobia, is lacking.  
113 There is a need for a systematic review that includes intervention studies assessing and/or treating  
114 FA by appreciating its components on chronic musculoskeletal pain, as it is more patient-tailored  
115 and clinically useful. As such, utilising this study's interpretation of the FA model will influence the  
116 search criteria to include all relevant study designs and the current measures of FA components.

117 Finally, the voice of community collaborators, such as patients, carers, and allied health  
118 professionals is vital in ensuring patient-centred conclusions and recommendations for assessment  
119 and interventions of FA in musculoskeletal health. Therefore, the objectives of this systematic  
120 review are as follows:

- 121 1. Identify and characterise interventions used to treat FA in people with chronic  
122 musculoskeletal pain by considering all study designs, relevant measures, and FA synonyms;
- 123 2. evaluate the use of common FA model-related measures that assess treatment  
124 interventions in people with chronic musculoskeletal pain;
- 125 3. engage with relevant community collaborators in the development of the systematic review  
126 search methodology and, at completion, to provide reflections on the findings and ensure  
127 further research to be clinically relevant.

## 128 **Methods**

129 This protocol will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analysis  
130 Protocols (PRISMA-P) reporting guidelines (25). This study is registered with PROSPERO (INSERT ID  
131 FOLLOWING PEER REVIEW) and will be conducted between 1<sup>st</sup> July 2024 – 1<sup>st</sup> September 2024.

### 132 Patient and Public Involvement Statement (PPI)

133 A panel of patients with chronic pain who attended the Royal National Orthopaedic Hospital, UK  
134 attended an online focus group about chronic pain and were reimbursed for their time. The nature  
135 of this PPI is an involvement activity, where the opinions of community collaborators were collected  
136 on the topic of FA, and so ethical approval is not required. Regarding kinesiophobia, patients spoke  
137 about the importance of early intervention, education, and rehabilitation from encouraging,  
138 knowledgeable, and positive health professionals. Within the discussion, participants mentioned  
139 other aspects of fear avoidance, such as catastrophisation, and were concerned that their fear of  
140 movement would never fully disappear but felt hopeful that it could be dampened with correct

141 management. Participants all agreed that peer support was vital to their personal ‘journey’ in  
142 managing fear of movement. Moreover, a concern was raised about how a participant felt that they  
143 were unable to take part in research studies due to their comorbidities, and so consequently  
144 believed that their views and experiences were not reflected in the research.

145 The authors felt that the term ‘kinesiophobia’ was quite uncommon among allied health  
146 professionals, musculoskeletal researchers, and patients, and that research may exist on this topic  
147 without naming it in such a way, and consequently be missed by systematic review searches. To  
148 combat this, the aim was to reach multiple health professionals to consider their understanding of  
149 kinesiophobia so that they could offer the terminology they use with other clinicians or their  
150 patients. The authors circulated the following question on X<sup>i</sup> (formerly Twitter),

151 *Calling ALL health professionals! What do you mean when you say \*kinesiophobia\*? Please*  
152 *comment below + include a description of your job role + share with your network.*

153 This resulted in 20,001 impressions, 727 engagements, 23 retweets and 37 comments. Direct  
154 responses came from 36 individuals, representing physiotherapists, musculoskeletal researchers,  
155 orthopaedic surgeons, pain management clinicians, chiropractors, and sports trainers. Examples of  
156 responses include,

157 *“...being scared to move too much for fear of triggering a flare up of pain.”*

158 *“...rationale of irrational fear of causing or increasing tissue damage...”*

159 *“when an individual doesn’t have the knowledge, skills and/or confidence to move their*  
160 *body...”*

161 *“I don’t tend to use the word clinically however, in children+young[sic] people I would*  
162 *describe kinesiophobia as the loss of spontaneous, fluent and playful movement due to a*  
163 *memory or thought that links movement to a negative and feared consequence...”*

164 *“...no patient has ever used the term unless learnt from a clinician.”*

165 *“...I don’t like when it’s describe[sic] as “irrational” fear it makes me feel like we’re blaming*  
166 *the person.”*

167 *“...delineating terms may help us work more effectively with patients...”*

168 These interactions subsequently informed the design of our search terms and inclusion/exclusion  
169 criteria.

170 In addition to this protocol being informed by PPI, results of this systematic review will be shared  
171 with another focus group including patients, carers, and health professionals to discuss their  
172 impression of the findings and potential for impact on them, to gauge how well their experience is  
173 represented by the findings and generate ideas for future research.

#### 174 Eligibility criteria

175 Eligible studies include primary interventional research articles in English or with an available English  
176 translation. The FA model was initially outlined by Lethem et al (26) and studies that explored  
177 psychological factors in chronic pain were increasingly prevalent in the 1970s, so the date range for  
178 included reports will be from 1970 onwards.

#### 179 Information sources

180 Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, The Allied and  
181 Complementary Medicine Database (AMED), PEDro, Web of Science, and grey literature (e.g.,  
182 medRxiv, ISRCTN protocol registry) will be searched using database-specific syntax detailed below.  
183 Reference lists of resulting articles will be searched for articles previously missed. The final list of  
184 selected articles will be entered into Connected Papers<sup>ii</sup>, which will also search for associated papers  
185 that could have been missed.

#### 186 Search strategy

187 The search strategy will be formulated using the Peer Review of Electronic Search Strategies (PRESS)  
188 Evidence-Based Checklist (27). The searches will be divided into three themes: [1] musculoskeletal



189 conditions, [2] FA components and their synonyms, and [3] relevant outcome measures. These  
190 themes will be combined with the Boolean operator "AND". Any restrictions outlined in the exclusion  
191 criteria will be combined cautiously, as to not remove relevant articles, with "NOT".

192 Ovid<sup>iii</sup> will be used for the AMED, Embase, and MEDLINE databases whilst CENTRAL and PEDro will be  
193 searched on their own respective search engines. Key search terms will be used for every database  
194 and logically matched with their respective subjecting headings or Medical Subject Headings (MeSH)  
195 term system. For instance, Ovid has a "Map Term to Subject Heading" option, whilst CENTRAL uses  
196 MeSH terms. The relevant subject headings are database-specific and will be exploded where  
197 necessary. If a subject heading system is unavailable, then a multi-purpose (mp) search would be  
198 used for the free-text key terms, i.e. several fields including title, abstract, and keywords (27).

199 The key search terms for the search strategy are:

- 200 1. **Search 1 (musculoskeletal conditions):** "pain", any MSK "-algia" conditions (e.g. causalgia,  
201 neuralgia, epicondyalgia, etc.), MSK pain, physical suffering, MSK pain (any body part, e.g.  
202 elbow, knee, neck, back, etc.), "phantom limb", "complex regional pain syndrome",  
203 "sciatica", "neuropath\*", arthritis (all forms, e.g. osteoarthritis, rheumatoid arthritis, etc.),  
204 "sacroilitis", "Failed back surgery syndrome", "persistent spinal pain syndrome", "whiplash"
- 205 2. **Search 2 (FA components):** kinesiophobi\*, "fear of mov\*", "fear of injur\*", "fear of reinjur\*",  
206 "fear of re-injur\*", "fear" AND "movement", "fear" AND "injur\*", "fear" AND "reinjur\*",  
207 "fear" AND "re-injur\*", "fear avoidance", "behavioural performance", "behavioral  
208 performance", "avoidance behaviour", "avoidance behavior", "pain-related fear",  
209 "avoidance of physical exertion", "avoidance hypervigilance", "impaired physical  
210 performance", "scared of movement", "mov\* anxiety", "avoidance learning",  
211 "catastrophiz\*", "maladaptive pain belief", "pain belief", "victimization"
- 212 3. **Search 3 (relevant outcome measures):** "Tampa Scale of Kinesiophobia", "Kinesiophobia  
213 Causes Scale", "Fear-Avoidance Beliefs Questionnaire", "Fear-Avoidance Components Scale",

214 "Athlete Fear-Avoidance Questionnaire", "Pain Anxiety Symptoms Scale", "Pain  
215 Catastrophizing Scale", "Patient-Reported Outcomes Measurement Information System Pain  
216 Interference"

217 4. **Search 4:** Search 1 AND Search 2 AND Search 3

218 5. **Search 5: Search 4 NOT exclusion criteria (e.g. postoperative populations)**

219 Table 1 shows an example search of the MEDLINE database using the Ovid platform:

220 **Table 1. Example search of the MEDLINE database on Ovid.**

1. pain/ or exp acutepain/ or exp arthralgia/ or exp back pain/ or exp chronic pain/ or exp musculoskeletal pain/ or exp neck pain/ or exp neuralgia/ or exp nociceptive pain/ or exp pain, intractable/ or exp pain, postoperative/ or exp pain, procedural/ or exp pain, referred/ or exp pelvic pain/ or exp Failed Back Surgery Syndrome/

2. physical suffer\*.mp.

3. exp Complex Regional Pain Syndromes/

4. exp musculoskeletal diseases/ or sciatica/

5. arthritis/ or exp arthritis, infectious/ or exp arthritis, psoriatic/ or exp arthritis, rheumatoid/ or exp gout/ or exp osteoarthritis/ or exp peri-arthritis/ or exp sacroiliitis/ or exp spondylarthritis/

6. exp Neuropathology/

7. exp neck injuries/ or whiplash injuries/

8. exp catastrophization/ or exp kinesiophobia/

9. catastroph?\*.mp.

10. kinesiophobi\*.mp.

11. Avoidance Learning/

12. "fear of movement".mp.

13. "fear AND movement".mp.

14. "fear of injur\* ".mp.

15. "fear of reinjur\* ".mp.

16. "fear of re-injur\* ".mp.

17. (fear and injur\* ).mp.

18. (fear and reinjur\* ).mp.

19. (fear and re-injur\* ).mp.

20. "fear avoidance\* ".mp.

21. "behavioural performance".mp.

22. "behavioral performance".mp.

23. "pain-related fear\* ".mp.

24. "avoidance behaviour\*".mp.
25. "avoidance behavior\*".mp.
26. (avoidance and physical exertion).mp.
27. impaired physical performance.mp
28. "Tampa scale of kinesiophobia".mp.
29. Fear-Avoidance Beliefs Questionnaire.mp.
30. "Athlete Fear-Avoidance Questionnaire".mp.
31. "Fear-Avoidance Components Scale".mp.
32. "Kinesiophobia Causes Scale".mp.
33. "Pain Anxiety Symptoms Scale".mp.
  
34. Patient-Reported Outcomes Measurement Information System Pain Interference.mp.
  
35. Pain Catastrophizing Scale.mp.
36. 1 or 2 or 3 or 4 or 5 or 6 or 7
37. 8 or 9 or 10 or 11 or 12 or 13 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27
38. 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35
39. 36 AND 37 AND 38
  
40. exp anterior cruciate ligament reconstruction/ or exp arthroplasty, replacement/ or exp arthroplasty, replacement, ankle/ or exp arthroplasty, replacement, elbow/ or exp arthroplasty, replacement, finger/ or exp arthroplasty, replacement, hip/ or exp arthroplasty, replacement, knee/ or exp arthroplasty, replacement, shoulder/ or exp hemiarthroplasty/ or exp total disc replacement/ or exp arthroscopy/ or exp diskectomy/ or exp meniscectomy/ or exp decompression, surgical/ or exp diskectomy/ or exp laminectomy/
  
41. 39 NOT 40

222 In this example search, “exp” is the function at which Ovid uses to expand the search for all terms  
223 under the subject heading, and “mp” refers to multi-purpose and searches for all relevant fields if  
224 the term is free text.

225 Study records

226 *Data management*

227 Search results will be exported from the database and compiled in Rayyan<sup>iv</sup>. Rayyan is an online tool  
228 that is designed for screening reports in systematic reviews and allows convenient collaboration  
229 amongst the researchers, such as with remote working. There is also an additional feature that

230 allows the automatic detection and removal of duplicates, which will be done at the 95% confidence  
231 threshold within the Rayyan settings.

### 232 *Selection process*

233 Using Rayyan, three researchers including clinicians and academics (ST, FW, AJ) will independently  
234 review the search results to deem whether studies meet predetermined inclusion/exclusion criteria  
235 using the title and abstract. The full text of remaining studies will be reviewed independently to  
236 determine final inclusion in the systematic review. Where disagreements occur, an impartial  
237 researcher (AT) will help reach resolution through group discussion. A flow diagram will be produced  
238 showing papers excluded at each stage, along with the reason.

### 239 *Inclusion criteria*

240 Papers describing individuals of any sex who are aged  $\geq 18$ -years old and targeting chronic pain  
241 resulting from any musculoskeletal condition will be included in this study. Included studies can  
242 contain homogenous or heterogenous populations and individual participants can experience  
243 multiple comorbid conditions. Any intervention (e.g. physical, psychiatric, educational, psychosocial,  
244 behavioural) will be included with or without comparison to a control group, and regardless of  
245 outcome. The intervention must target FA and/or its components by the context of the study. The  
246 questionnaire used to assess FA and/or its components can either be primary or secondary outcome.  
247 The included questionnaires used to measure fear avoidance are outlined in search 3 of the above  
248 search strategy. Studies will be considered regardless of setting, time frame, or treatment length. No  
249 limits nor filters will be used to restrict the study designs included.

### 250 *Exclusion criteria*

251 Studies on children, solely healthy subjects, non-musculoskeletal fear avoidance (e.g., neurological  
252 origin in people with Parkinson's or Multiple Sclerosis, or visceral pain), and postoperative  
253 populations (e.g. following total knee arthroplasty) will be excluded. Review articles and secondary  
254 analysis papers will be excluded.

255 *Data collection process*

256 A data collection form detailing all data items will be used to extract information for included papers  
257 by a single researcher. Where data is missing, two attempts will be made to contact the  
258 corresponding author of the papers at two-week intervals, to retrieve the necessary information.

259 Data items

260 Study identifiers, study design, cohort size, cohort location, intervention, participant gender,  
261 participant age, cohort diagnosis/disorder, cohort symptom characteristics, cohort comorbid  
262 diagnoses, treatment period (e.g., 6-months), outcome measure (e.g., TSK), treatment outcome,  
263 comparative group (where applicable), power (where applicable and achievable), effect size (where  
264 applicable and achievable), level of evidence for therapeutic studies (28).

265 Outcomes and prioritisation

266 The primary outcome will be a list of the identified and characterised treatment interventions used  
267 to treat FA components and the questionnaires used to assess outcome. Secondary outcomes will be  
268 the opinion of community collaborators through PPI to provide reflections and develop a list of  
269 future research priorities.

270 Risk of bias of individual studies

271 For RCTs, the Risk of Bias (ROB) 2.0 tool (29) will be used to assess the risk of bias. For non-  
272 randomised studies, the Risk of Bias In Non-randomised Studies – of Interventions (ROBINS-I) tool  
273 (30) will be used. This tool considers that each study is attempting to mimic an RCT and judges them  
274 on similarly thorough criteria in seven domains that could affect bias. Analysis of bias will be carried  
275 out for all included studies twice between two reviewers (ST, FW) independently. Where  
276 disagreements occur, discussion led by a mediator (AT) will aim to resolve differences and result in  
277 agreement. Both tools utilise relevant cut-off points that categorises the risk of bias as either "low  
278 risk of bias", "some concerns", or "high risk of bias".

## 279 Data synthesis

280 The identification and extraction of core themes from included papers will be performed using a  
281 combined reflexive thematic analysis and realist synthesis approach (32-35). Reflexive thematic  
282 analyses and associated thematic networks are established qualitative analytical tools designed to  
283 reveal and organise themes in a hierarchical manner through a structured approach. The themes  
284 generated during reflexive thematic analysis will be tested and interpreted by key community  
285 collaborators in the PPI groups; these interpretations will be integrated with the reflexive thematic  
286 analysis data through and adapted realist synthesis methodology. Realist synthesis has been applied  
287 to systematic reviews to uncover the mechanisms underpinning interventions positioned within  
288 contextual factors. This combination of established qualitative approaches will enable the robust  
289 integration of the systematic review and PPI reflexive data to better appreciate multiple  
290 perspectives on interventions.

## 291 Meta-biases

292 Tabulation and visual display of the individual risk of bias assessments will be created. Due to the  
293 assumed heterogenous nature of the gathered studies, it will not be feasible to conduct a meta-  
294 analysis.

## 295 Confidence in cumulative evidence

296 The Grading of Recommendations Assessment, Development and Evaluation (GRADE) method will  
297 be used to assess the quality of evidence for all outcomes (35). This includes risk of bias, consistency,  
298 directness, precision, and publication bias. This will result in allocation of a high, moderate, low, or  
299 very low-quality study label.

## 300 **Discussion**

301 This systematic review will provide and characterise a broad overview of interventions intended to  
302 treat FA and evaluate the questionnaires used to assess their outcomes. Until now, many systematic

303 reviews have focused on kinesiophobia as a single aspect of the FA model, rather than a more  
304 holistic approach, as is proposed here. A broad perspective of treatment interventions for FA related  
305 to chronic pain in musculoskeletal conditions could educate medical professionals and highlight  
306 areas of further research. Understanding how the outcome of these studies are assessed using  
307 questionnaires will allow recommendations to be made for future research and a stronger inclusion  
308 of the whole FA model rather than purely kinesiophobia.

309 A limitation of this protocol is the inclusion of participants with comorbidities because FA often  
310 results from, or is commonly comorbid with, other diagnoses. Whilst this will increase the risk of  
311 bias, it will ensure results are more generalisable (36), in keeping with our PPI focus group findings.  
312 Additionally, all types of study are included, rather than just RCTs, so assessment of risk of bias will  
313 be an important factor when drawing conclusions from this study, but we felt it was important to  
314 give a broad perspective at this stage.

315 In carrying out this work, we also hope to introduce an interesting PPI framework that could be used  
316 and expanded upon in future systematic review protocols. Public involvement could empower  
317 people with chronic musculoskeletal pain to take ownership of their treatment and seek out  
318 knowledgeable professionals who deliver evidence-based care. Additionally, it will ensure our  
319 research aims, perspectives and priorities are informed and directed by the exact population we aim  
320 to help.

321 **Word Count:** 3269

## 322 **References**

- 323 1. Zale EL, Ditre JW. Pain-Related Fear, Disability, and the Fear-Avoidance Model of Chronic  
324 Pain. *Curr Opin Psychol.* 2015;5:24-30.
- 325 2. Vlaeyen JWS, Crombez G, Linton SJ. The fear-avoidance model of pain. *Pain.*  
326 2016;157(8):1588-9.
- 327 3. Linton SJ, Shaw WS. Impact of psychological factors in the experience of pain. *Phys Ther.*  
328 2011;91(5):700-11.
- 329 4. Vlaeyen JWS, Linton SJ. Fear-avoidance and its consequences in chronic musculoskeletal  
330 pain: a state of the art. *Pain.* 2000;85(3):317-32.
- 331 5. Dover G, Amar V. Development and Validation of the Athlete Fear Avoidance Questionnaire.  
332 *J Athl Train.* 2015;50(6):634-42.
- 333 6. Crombez G, Eccleston C, Van Damme S, Vlaeyen JWS, Karoly P. Fear-Avoidance Model of  
334 Chronic Pain. The Next Generation. *Journal of Clinical Pain.* 2012;28:475-83.
- 335 7. Neblett R, Mayer TG, Hartzell MM, Williams MJ, Gatchel RJ. The Fear-avoidance Components  
336 Scale (FACS): Development and Psychometric Evaluation of a New Measure of Pain-related Fear  
337 Avoidance. *Pain Pract.* 2016;16(4):435-50.
- 338 8. Sandborgh M, Johansson AC, Soderlund A. The Relation between the Fear-Avoidance Model  
339 and Constructs from the Social Cognitive Theory in Acute WAD. *Pain Res Manag.*  
340 2016;2016:8281926.
- 341 9. Bordeleau M, Vincenot M, Lefevre S, Duport A, Seggio L, Breton T, et al. Treatments for  
342 kinesiophobia in people with chronic pain: A scoping review. *Front Behav Neurosci.* 2022;16:933483.
- 343 10. Trost Z, France CR, Thomas JS. Pain-related fear and avoidance of physical exertion following  
344 delayed-onset muscle soreness. *Pain.* 2011;152(7):1540-7.
- 345 11. Swinkels-Meewisse IE, Roelofs J, Verbeek AL, Oostendorp RA, Vlaeyen JW. Fear of  
346 movement/(re)injury, disability and participation in acute low back pain. *Pain.* 2003;105(1-2):371-9.
- 347 12. Hasenbring MI, Verbunt JA. Fear-avoidance and endurance-related responses to pain: new  
348 models of behavior and their consequences for clinical practice. *Clin J Pain.* 2010;26(9):747-53.
- 349 13. van Wilgen CP, Dijkstra PU, Versteegen GJ, Fleuren MJ, Stewart R, van Wijhe M. Chronic pain  
350 and severe disuse syndrome: long-term outcome of an inpatient multidisciplinary cognitive  
351 behavioural programme. *J Rehabil Med.* 2009;41(3):122-8.
- 352 14. Domingues de Freitas C, Costa DA, Junior NC, Civile VT. Effects of the pilates method on  
353 kinesiophobia associated with chronic non-specific low back pain: Systematic review and meta-  
354 analysis. *J Bodyw Mov Ther.* 2020;24(3):300-6.



- 355 15. Hanel J, Owen PJ, Held S, Tagliaferri SD, Miller CT, Donath L, Belavy DL. Effects of Exercise  
356 Training on Fear-Avoidance in Pain and Pain-Free Populations: Systematic Review and Meta-analysis.  
357 Sports Med. 2020;50(12):2193-207.
- 358 16. Jadhakhan F, Sobeih R, Falla D. Effects of exercise/physical activity on fear of movement in  
359 people with spine-related pain: protocol for a systematic review and meta-analysis. BMJ Open.  
360 2022;12(5):e060264.
- 361 17. Xu Y, Song Y, Sun D, Fekete G, Gu Y. Effect of Multi-Modal Therapies for Kinesiophobia  
362 Caused by Musculoskeletal Disorders: A Systematic Review and Meta-Analysis. Int J Environ Res  
363 Public Health. 2020;17(24).
- 364 18. Miller RP, Kori SH, Todd DD. The Tampa Scale: a Measure of Kinisophobia. The Clinical  
365 Journal of Pain. 1991;7(1):51.
- 366 19. Liu H, Huang L, Yang Z, Li H, Wang Z, Peng L. Fear of Movement/(Re)Injury: An Update to  
367 Descriptive Review of the Related Measures. Front Psychol. 2021;12:696762.
- 368 20. Waddell G, Newton M, Henderson I, Somerville D, Main CJ. A Fear-Avoidance Beliefs  
369 Questionnaire (FABQ) and the role of fear-avoidance beliefs in chronic low back pain and disability.  
370 Pain. 1993;52(2):157-68.
- 371 21. Knapik A, Saulicz E, Gnat R. Kinesiophobia - introducing a new diagnostic tool. J Hum Kinet.  
372 2011;28:25-31.
- 373 22. Kamonseki DH, Christenson P, Rezvanifar SC, Calixtre LB. Effects of manual therapy on fear  
374 avoidance, kinesiophobia and pain catastrophizing in individuals with chronic musculoskeletal pain:  
375 Systematic review and meta-analysis. Musculoskelet Sci Pract. 2021;51:102311.
- 376 23. Lundberg M, Grimby-Ekman A, Verbunt J, Simmonds MJ. Pain-related fear: a critical review  
377 of the related measures. Pain Res Treat. 2011;2011:494196.
- 378 24. Wideman TH, Asmundson GGJ, Smeets R, Zautra AJ, Simmonds MJ, Sullivan MJL, et al.  
379 Rethinking the fear avoidance model: toward a multidimensional framework of pain-related  
380 disability. Pain. 2013;154(11):2262-5.
- 381 25. Shamseer L, Moher D, Clarke M, Gherzi D, Liberati A, Petticrew M, et al. Preferred reporting  
382 items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and  
383 explanation. BMJ. 2015;350:g7647.
- 384 26. Lethem J, Slade PD, Troup JD, Bentley G. Outline of a Fear-Avoidance Model of exaggerated  
385 pain perception--I. Behav Res Ther. 1983;21(4):401-8.
- 386 27. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review  
387 of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol. 2016;75:40-6.

- 388 28. Medicine CfE-B. Oxford Centre for Evidence-Based Medicine: Levels of Evidence (March  
389 2009): Centre for Evidence-Based Medicine; 2009 [Available from:  
390 [https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-  
392 medicine-levels-of-evidence-march-2009](https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-<br/>391 medicine-levels-of-evidence-march-2009).  
393 29. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool  
394 for assessing risk of bias in randomised trials. *BMJ*. 2019;366:l4898.  
395 30. Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a  
396 tool for assessing risk of bias in non-randomised studies of interventions. *BMJ*. 2016;355:i4919.  
397 31. Strauss A, Corbin JM. *Basics of qualitative research: Grounded theory procedures and  
398 techniques*. Thousand Oaks, CA, US: Sage Publications, Inc; 1990. 270- p.  
399 32. Attride-Stirling J. Thematic networks: an analytic tool for qualitative research. *Qualitative  
400 Research*. 2001;1(3):385-405.  
401 33. Braun, V., Clarke, V., Hayfield, N., Davey, L. and Jenkinson, E., 2023. Doing reflexive thematic  
402 analysis. In *Supporting Research in Counselling and Psychotherapy: Qualitative, Quantitative, and  
403 Mixed Methods Research* (pp. 19-38). Cham: Springer International Publishing.  
404 34. Hunter R, Gorely T, Beattie M, Harris K. Realist review. *International Review of Sport and  
405 Exercise Psychology*. 2022;15(1):242-65.  
406 35. Rycroft-Malone J, McCormack B, Hutchinson AM, DeCorby K, Bucknall TK, Kent B, et al.  
407 Realist synthesis: illustrating the method for implementation research. *Implement Sci*. 2012;7:33.  
408 36. Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al. GRADE guidelines:  
409 11. Making an overall rating of confidence in effect estimates for a single outcome and for all  
410 outcomes. *J Clin Epidemiol*. 2013;66(2):151-7.  
411 37. Drucker AM, Fleming P, Chan AW. *Research Techniques Made Simple: Assessing Risk of Bias  
412 in Systematic Reviews*. *J Invest Dermatol*. 2016;136(11):e109-e14.

---

<sup>i</sup> [www.twitter.com](https://www.twitter.com)

<sup>ii</sup> <https://www.connectedpapers.com/>

<sup>iii</sup> <https://ovidsp.dc1.ovid.com/ovid-new-a/ovidweb.cgi>

<sup>iv</sup> <https://www.rayyan.ai/>

Fear Avoidance




Figure 1